Evidence map›Paper›PMID 36620922›Full record

ReviewPharmaceutical biology2023

Advances for pharmacological activities of

Jia Ke, Meng-Ting Li, Shuyang Xu, Jianpeng Ma, Ming-Yuan Liu, Yan Han

Abstract readReview
In one paragraph

Review in Pharmaceutical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Resveratrol-EnrichedNutrients · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. 2-Methoxystypandrone fromAntioxidants (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Stabilizing the Baseline: Reference Gene Evaluation in Three InvasiveInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jia KeDepartment of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0002-6072-9800
Meng-Ting LiDepartment of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0002-2286-9001
Shuyang XuMonteverde Academy Shanghai, Shanghai, China.
Jianpeng MaMultiscale Research Institute of Complex Systems, Fudan University, Shanghai, China.
Ming-Yuan LiuDepartment of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0002-1952-1012
Yan HanDepartment of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0002-7654-0906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

context

objectiveThis article reviews the pharmacological action and the clinical applications of

methodsThe data were retrieved from major medical databases, such as CNKI, PubMed, and SinoMed, from 2014 to 2022.

resultsThe rhizomes, leaves, and flowers of

conclusions

Indexed as

Fallopia japonicaPlants, MedicinalPolygonumMedicine, Chinese TraditionalPhytochemicalsPlant ExtractsPhytochemicalsPlant Extractsanticanceranti-inflammatoryChinese herbheart protectionHuzhangpharmacokinetics

Identifiers

PMID36620922
PMCPMC9833411

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.